Beijing Cancer Prevention & Treatment Society

This study looks at people with advanced non-small cell lung cancer that has a specific EGFR gene change. After 3 weeks on the standard targeted drug osimertinib, those whose cancer still shows the gene change in their blood are randomly assigned to either keep taking osimertinib…